CAS 2109805-56-1

Fórmula: C28H30N6O2

InChI: InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)

Chave InChI: IEFFSHLHNYVSEF-UHFFFAOYSA-N

SMILES: CC(C)(C1=CC=C(C=C1)C(=O)NC2=CN3C=C(C=CC3=N2)C4=CC=NC=C4)C(=O)N5CCN(CC5)C

CLK-IN-T3

CAS: 2109805-56-1

CLK-IN-T3

Fórmula: C₂₈H₃₀N₆O₂

Pureza: 99.5%

Peso molecular: 482.58

Ref: 54-BUP04185

4-(2-Methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide

CAS: 2109805-56-1

Fórmula: C₂₈H₃₀N₆O₂

Pureza: 99%

Cor e Forma: Solid

Peso molecular: 482.5768

Ref: IN-DA01V3MD

4-(2-Methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide

CAS: 2109805-56-1

4-(2-Methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide

Fórmula: C₂₈H₃₀N₆O₂

Pureza: 99%

Peso molecular: 482.58

Ref: IN-DG767573

CLK-IN-T3

CAS: 2109805-56-1

CLK-IN-T3 is a small molecule that has been shown to induce apoptosis in cancer cells. CLK-IN-T3 induces the activation of caspase 3, which is involved in the execution phase of apoptosis. CLK-IN-T3 also synergizes with other chemotherapeutic agents, such as doxorubicin and vincristine, to induce cell death. CLK-IN-T3 has been shown to inhibit neurodevelopmental processes and enhances apoptotic signaling pathways in hCT116 colon cancer cells. This drug may be useful for combination strategies for cancer therapy.

Fórmula: C₂₈H₃₀N₆O₂

Pureza: Min. 95%

Peso molecular: 482.6 g/mol

Ref: 3D-JJD80556

CLK-IN-T3

CAS: 2109805-56-1

CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.

Fórmula: C₂₈H₃₀N₆O₂

Pureza: 99.61%

Cor e Forma: Solid

Peso molecular: 482.5768

Ref: TM-T14980